{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:51:51Z","timestamp":1772009511343,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.pcad.2009.11.005","type":"journal-article","created":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T02:02:58Z","timestamp":1269223378000},"page":"383-392","source":"Crossref","is-referenced-by-count":31,"title":["Congestion as a Therapeutic Target in Acute Heart Failure Syndromes"],"prefix":"10.1016","volume":"52","author":[{"given":"Steven R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Brandimarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2009.11.005_bib1","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1161\/CIRCULATIONAHA.105.590091","article-title":"International Working Group on Acute heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research","volume":"112","author":"Gheorghiade","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.005_bib2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa0706824","article-title":"Cardiac troponin and outcome in acute heart failure","volume":"358","author":"Adams","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.11.005_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCHEARTFAILURE.107.746933","article-title":"Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF)","volume":"1","author":"Klein","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2009.11.005_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jacc.2003.07.031","article-title":"Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure","volume":"43","author":"Forman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jacc.2006.07.073","article-title":"Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure","volume":"49","author":"Costanzo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","article-title":"Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"149","author":"Adams","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2009.11.005_bib7","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.296.18.2217","article-title":"Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure","volume":"296","author":"Gheorghiade","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.005_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10741-005-6127-6","article-title":"Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry","volume":"9","author":"Fonarow","year":"2004","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pcad.2009.11.005_bib9","first-page":"1308","article-title":"Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain","volume":"44","author":"Weber","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib10","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","article-title":"Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial","volume":"9","author":"Hasselblad","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2009.11.005_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/hrt.75.4.349","article-title":"Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide","volume":"75","author":"Dormans","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2009.11.005_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000047398","article-title":"Clinical benefit and approach of ultrafiltration in acute heart failure","volume":"96","author":"Sharma","year":"2001","journal-title":"Cardiology"},{"key":"10.1016\/j.pcad.2009.11.005_bib13","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0735-1097(01)01479-6","article-title":"Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure","volume":"38","author":"Marenzi","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0002-9343(87)90495-5","article-title":"Hemofiltration as short-term treatment for refractory congestive heart failure","volume":"83","author":"Rimondini","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2009.11.005_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1054\/jcaf.2003.28","article-title":"Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients","volume":"9","author":"Jaski","year":"2003","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2009.11.005_bib16","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jacc.2005.05.098","article-title":"Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial","volume":"46","author":"Bart","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"10 Suppl A","key":"10.1016\/j.pcad.2009.11.005_bib17","first-page":"A48","article-title":"Changes in GFR, BUN and BUN\/creatinine during treatment of heart failure and volume overload with ultrafiltration or intravenous diuretics","volume":"51","author":"Bart","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(88)91851-X","article-title":"Raised venous pressure: a direct cause of renal sodium retention in oedema","volume":"1","author":"Firth","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.11.005_bib19","article-title":"Improvement in cardiorenal syndrome with ultrafiltration","author":"Bart","year":"2009","journal-title":"J Card Fail"},{"issue":"Suppl 2","key":"10.1016\/j.pcad.2009.11.005_bib20","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/j.cardfail.2007.06.715","article-title":"The improved outcomes following ultrafiltration versus intravenous diuretics in UNLOAD are not solely due to increased weight loss in the ultrafiltration group","volume":"13","author":"Bart","year":"2007","journal-title":"J Cardiac Fail"},{"key":"10.1016\/j.pcad.2009.11.005_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0290001","article-title":"Vasopressin V2 receptor antagonists","volume":"29","author":"Verbalis","year":"2002","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.pcad.2009.11.005_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.005_bib23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.005_bib24","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.005_bib25","first-page":"1382","article-title":"Efficacy and safety of conivaptan in acute decompensated heart failure, a dose ranging pilot study","volume":"14","author":"Goldsmith","year":"2009","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pcad.2009.11.005_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2009.11.005_bib27","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.005_bib28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin v2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib29","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/17482940701210179","article-title":"Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial","volume":"9","author":"Rossi","year":"2007","journal-title":"Acute Card Care"},{"issue":"2 Pt 2","key":"10.1016\/j.pcad.2009.11.005_bib31","first-page":"F227","article-title":"Synergistic effects of angiotensin and adenosine in the renal microvasculature","volume":"266","author":"Weihprecht","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI8761","article-title":"Adenosine formed by 5\u2032-nucleotidase mediates tubuloglomerular feedback","volume":"106","author":"Thomson","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2009.11.005_bib33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cardfail.2007.08.006","article-title":"The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment","volume":"13","author":"Dittrich","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2009.11.005_bib34","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jacc.2007.07.019","article-title":"The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance","volume":"50","author":"Givertz","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib35","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jacc.2007.03.059","article-title":"Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study","volume":"50","author":"Greenberg","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib36","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.005_bib37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0735-1097(99)00532-X","article-title":"Effects of BG9719 (CVT-124), an A1-Adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure","volume":"35","author":"Gottlieb","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib38","article-title":"PROTECT Study: effects of rolofylline in patients with acute heart failue syndrome and renal impairment","author":"Metra","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2009.11.005_bib39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)08417-1","article-title":"Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema","volume":"351","author":"Cotter","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.11.005_bib40","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.287.12.1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.005_bib41","doi-asserted-by":"crossref","first-page":"18G","DOI":"10.1016\/j.amjcard.2005.07.017","article-title":"The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF)","volume":"96","author":"Gheorghiade","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib42","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/01.CIR.0000159340.93220.E4","article-title":"Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure","volume":"111","author":"Sackner-Bernstein","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.005_bib43","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","article-title":"Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials","volume":"293","author":"Sackner-Bernstein","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.005_bib44","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.005_bib45","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.11.005_bib46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.005_bib47","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: the SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.005_bib48","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1071-9164(03)00532-3","article-title":"Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study","volume":"9","author":"Packer","year":"2003","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2009.11.005_bib49","article-title":"The Rancomized multicenter EValuation of Intraveneous leVosimendan Efficacy-2 (REVIVE-2) trial. Late breaking clinical trials","author":"Packer","year":"2005"},{"key":"10.1016\/j.pcad.2009.11.005_bib50","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","article-title":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","volume":"41","author":"Felker","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib51","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.cardfail.2007.06.609","article-title":"Coadministration of the Vasopressin-2 Receptor Antagonist Tolvaptan and B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal or Neurohumoral Function in Experimental Congestive Heart Failure","author":"Costello-Boerrigter","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2009.11.005_bib52","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/CIRCULATIONAHA.107.737106","article-title":"Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action","volume":"117","author":"Elkayam","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.005_bib53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2008.02.077","article-title":"Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP","volume":"52","author":"Lisy","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib54","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.jacc.2007.07.078","article-title":"Long-term use of sildenafil in the therapeutic management of heart failure","volume":"50","author":"Guazzi","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib55","doi-asserted-by":"crossref","first-page":"47A","DOI":"10.1016\/j.amjcard.2006.09.006","article-title":"A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function","author":"Ghali","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib56","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.jacc.2008.03.015","article-title":"Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure","volume":"51","author":"Gheorghiade","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.005_bib57","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9149(83)80135-0","article-title":"Clonidine in congestive heart failure: a vasodilator with negative inotropic effects","volume":"51","author":"Hermiller","year":"1983","journal-title":"Am J Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062009000954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062009000954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T07:25:45Z","timestamp":1544599545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062009000954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0033062009000954"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2009.11.005","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}